Analysis of HIV-1 Replication During Antiretroviral Therapy
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00767312|
Recruitment Status : Enrolling by invitation
First Posted : October 7, 2008
Last Update Posted : January 15, 2019
This study will determine if the level of virus in HIV-infected patients taking antiretroviral medications for prolonged periods decreases or persists at a stable level. It will also examine whether new gene changes (mutations) occur during drug suppression.
HIV-infected patients who are 18 years of age or older, have been enrolled in another NIH protocol, have been suppressed on antiretroviral therapy and have very low levels of virus in their blood may be eligible for this 5-year (or more) study.
Participants come to the NIH Clinical Center about every 6 months for a physical examination, routine and research blood tests and leukapheresis to collect white blood cells for T cell analysis. For leukapheresis, blood is collected through a vein much like donating whole blood, but the blood is directed through a machine that separates and extracts the white cells and returns the rest of the blood components to the patient. Patients may also have an optional third clinic visit each year for another blood draw.
|Condition or disease|
|Study Type :||Observational|
|Actual Enrollment :||47 participants|
|Official Title:||Analysis of HIV-1 Replication During Antiretroviral Therapy|
|Study Start Date :||October 1, 2008|
HIV-infected patients who are 18 years of age or older, have been enrolled in another NIH protocol.
- We plan to investigate the relationship of HIV-1 viral RNA levels and genetic variation in patients on antiretroviral therapy over prolonged periods. [ Time Frame: End of Study ]
- 1. Investigate the determinants of HIV- 1 viremia in suppressed patients [ Time Frame: End of Study ]
- 3. Investigate the genetic and immunologic characteristics of patients with HIV-1 suppression on antiretroviral therapy who experience rebound viremia [ Time Frame: End of Study ]
- 2. Provide human subjects protection oversight for samples accrued in protocol 97-I-0082 and 00-I-0110 [ Time Frame: End of Study ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00767312
|United States, Maryland|
|National Institutes of Health Clinical Center, 9000 Rockville Pike|
|Bethesda, Maryland, United States, 20892|
|Principal Investigator:||Frank Maldarelli, M.D.||National Cancer Institute (NCI)|